

Global Benign Prostatic Hyperplasia Medication Market Research Report 2017-2022 by Players, Regions, Product Types & Applications

<https://marketpublishers.com/r/G6B95A3FCBFEN.html>

Date: July 2017

Pages: 125

Price: US\$ 2,380.00 (Single User License)

ID: G6B95A3FCBFEN

Abstracts

The global Benign Prostatic Hyperplasia Medication market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report offers an overview of the market trends, drivers, and barriers with respect to the Benign Prostatic Hyperplasia Medication market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Benign Prostatic Hyperplasia Medication market by by 5 α -reductase inhibitors, by α -receptor antagonist, by Plant Preparations, by Others, and application. Detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Benign Prostatic Hyperplasia Medication market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report focuses Global market, it covers details as following:

Key Players

MSD PHARMA (SINGAPORE) PTE.LTD.

Merck Sharp & Dohme Limited

GlaxoSmithKline (Ireland) Limited

Pfizer Pharma GmbH

Sanofi-Aventis France

ABBOTT LABORATORIES

Astellas Pharma Inc.

AMNEAL PHARMS

ANCHEN PHARMS

APOTEX INC

ASCENT PHARMS INC

AUROBINDO PHARMA

BARR

BIONPHARMA INC

BOEHRINGER INGELHEIM

BRECKENRIDGE PHARM

CIPLA LTD

AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad

Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure

CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village

CIPLA LIMITED IN 400 013 Mumbai

CRYSTAL PHARMA S.A.U. ES 47151 Boecillo

DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad

EXCELLA GMBH & CO. KG DE 90537 Feucht

Farmak A.S. CZ 779 00 Olomouc

HETERO LABS LIMITED IN 500 018 Hyderabad

Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou

MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

Key Regions

North America

United States

Canada

Latin America

Mexico

Brazil

Argentina

Others

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Netherland

Others

Asia & Pacific

China

Japan

India

Korea

Australia

Southeast Asia

Indonesia

Thailand

Philippines

Vietnam

Singapore

Malaysia

Others

Africa & Middle East

South Africa

Egypt

Turkey

Saudi Arabia

Iran

Others

Main types of products

Benign Prostatic Hyperplasia Medication Market, by 5 α -reductase inhibitors

Finasteride

Dutasteride

Epristeride

Benign Prostatic Hyperplasia Medication Market, by α -receptor antagonist

Pheoxbenzamine

Doxazosin

Alfuzosin

Terazosin

Prarizonaosin

Tamsulosin

Naftopidil

Benign Prostatic Hyperplasia Medication Market, by Plant Preparations

Prostat

Cernilton

Compound blue palm fruit

Benign Prostatic Hyperplasia Medication Market, by Others

Flavoxate

glu-ala-glycine

Benign Prostatic Hyperplasia Medication Market, by Key Consumer

urinary surgery

Pharmacy

Hospital

Clinic

Contents

CHAPTER ONE METHODOLOGY AND DATA SOURCE

- 1.1 Methodology/Research Approach
 - 1.1.1 Research Programs/Design
 - 1.1.2 Market Size Estimation
 - 1.1.3 Market Breakdown and Data Triangulation
- 1.2 Data Source
 - 1.2.1 Secondary Sources
 - 1.2.2 Primary Sources
- 1.3 Disclaimer

CHAPTER TWO BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET OVERVIEW

- 2.1 Market Coverage
- 2.2 Global Benign Prostatic Hyperplasia Medication Market Sales Volume Revenue and Price 2012-2017

CHAPTER THREE BENIGN PROSTATIC HYPERPLASIA MEDICATION BY KEY PLAYERS 2012-2017

- 3.1 Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players 2012-2017
- 3.2 Global Benign Prostatic Hyperplasia Medication Revenue Share by Key Players 2012-2017
- 3.3 Global Key Players Benign Prostatic Hyperplasia Medication Key Product Model and Market Performance
- 3.4 Global Key Players Benign Prostatic Hyperplasia Medication Key Target Consumers and Market Performance

CHAPTER FOUR BENIGN PROSTATIC HYPERPLASIA MEDICATION BY REGIONS 2012-2017

- 4.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions 2012-2017
- 4.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions 2012-2017

4.3 Global Benign Prostatic Hyperplasia Medication Price by Regions 2012-2017

4.4 North America

4.4.1 United States

4.4.2 Canada

4.5 Latin America

4.5.1 Mexico

4.5.2 Brazil

4.5.3 Argentina

4.5.4 Others in Latin America

4.6 Europe

4.6.1 Germany

4.6.2 United Kingdom

4.6.3 France

4.6.4 Italy

4.6.5 Spain

4.6.6 Russia

4.6.7 Netherland

4.6.8 Others in Europe

4.7 Asia & Pacific

4.7.1 China

4.7.2 Japan

4.7.3 India

4.7.4 Korea

4.7.5 Australia

4.7.6 Southeast Asia

4.7.6.1 Indonesia

4.7.6.2 Thailand

4.7.6.3 Philippines

4.7.6.4 Vietnam

4.7.6.5 Singapore

4.7.6.6 Malaysia

4.7.6.7 Others in Southeast Asia

4.8 Africa & Middle East

4.8.1 South Africa

4.8.2 Egypt

4.8.3 Turkey

4.8.4 Saudi Arabia

4.8.5 Iran

4.8.6 Others in Africa & Middle East

CHAPTER FIVE BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET BY PRODUCT TYPES

5.1 Benign Prostatic Hyperplasia Medication, by 5 α -reductase inhibitors 2012-2017

5.1.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5 α -reductase inhibitors 2012-2017

5.1.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5 α -reductase inhibitors 2012-2017

5.1.3 Global Benign Prostatic Hyperplasia Medication Price by 5 α -reductase inhibitors 2012-2017

5.1.4 Finasteride

5.1.5 Dutasteride

5.1.6 Epristeride

5.2 Benign Prostatic Hyperplasia Medication, by α -receptor antagonist 2012-2017

5.2.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by α -receptor antagonist 2012-2017

5.2.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α -receptor antagonist 2012-2017

5.2.3 Global Benign Prostatic Hyperplasia Medication Price by α -receptor antagonist 2012-2017

5.2.4 Pheoxbenzamine

5.2.5 Doxazosin

5.2.6 Alfuzosin

5.2.7 Terazosin

5.2.8 Prarizonaosin

5.2.9 Tamsulosin

5.2.10 Naftopidil

5.3 Benign Prostatic Hyperplasia Medication, by Plant Preparations 2012-2017

5.3.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations 2012-2017

5.3.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations 2012-2017

5.3.3 Global Benign Prostatic Hyperplasia Medication Price by Plant Preparations 2012-2017

5.3.4 Prostat

5.3.5 Cernilton

5.3.6 Compound blue palm fruit

5.4 Benign Prostatic Hyperplasia Medication, by Others 2012-2017

5.4.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others 2012-2017

5.4.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others 2012-2017

5.4.3 Global Benign Prostatic Hyperplasia Medication Price by Others 2012-2017

5.4.4 Flavoxate

5.4.5 glu-ala-glycine

CHAPTER SIX GLOBAL KEY PLAYERS PROFILE

6.1 MSD PHARMA (SINGAPORE) PTE.LTD.

6.1.1 MSD PHARMA (SINGAPORE) PTE.LTD. Company Details and Competitors

6.1.2 MSD PHARMA (SINGAPORE) PTE.LTD. Key Benign Prostatic Hyperplasia Medication Models and Performance

6.1.3 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.1.4 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.2 Merck Sharp & Dohme Limited

6.2.1 Merck Sharp & Dohme Limited Company Details and Competitors

6.2.2 Merck Sharp & Dohme Limited Key Benign Prostatic Hyperplasia Medication Models and Performance

6.2.3 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.2.4 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.3 GlaxoSmithKline (Ireland) Limited

6.3.1 GlaxoSmithKline (Ireland) Limited Company Details and Competitors

6.3.2 GlaxoSmithKline (Ireland) Limited Key Benign Prostatic Hyperplasia Medication Models and Performance

6.3.3 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.3.4 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.4 Pfizer Pharma GmbH

6.4.1 Pfizer Pharma GmbH Company Details and Competitors

6.4.2 Pfizer Pharma GmbH Key Benign Prostatic Hyperplasia Medication Models and Performance

6.4.3 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Business SWOT

Analysis and Forecast

6.4.4 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.5 Sanofi-Aventis France

6.5.1 Sanofi-Aventis France Company Details and Competitors

6.5.2 Sanofi-Aventis France Key Benign Prostatic Hyperplasia Medication Models and Performance

6.5.3 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.5.4 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.6 ABBOTT LABORATORIES

6.6.1 ABBOTT LABORATORIES Company Details and Competitors

6.6.2 ABBOTT LABORATORIES Key Benign Prostatic Hyperplasia Medication Models and Performance

6.6.3 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.6.4 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.7 Astellas Pharma Inc.

6.7.1 Astellas Pharma Inc. Company Details and Competitors

6.7.2 Astellas Pharma Inc. Key Benign Prostatic Hyperplasia Medication Models and Performance

6.7.3 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.7.4 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.8 AMNEAL PHARMS

6.8.1 AMNEAL PHARMS Company Details and Competitors

6.8.2 AMNEAL PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance

6.8.3 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.8.4 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.9 ANCHEN PHARMS

6.9.1 ANCHEN PHARMS Company Details and Competitors

6.9.2 ANCHEN PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance

6.9.3 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.9.4 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.10 APOTEX INC

6.10.1 APOTEX INC Company Details and Competitors

6.10.2 APOTEX INC Key Benign Prostatic Hyperplasia Medication Models and Performance

6.10.3 APOTEX INC Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

6.10.4 APOTEX INC Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin

6.11 ASCENT PHARMS INC

6.12 AUROBINDO PHARMA

6.13 BARR

6.14 BIONPHARMA INC

6.15 BOEHRINGER INGELHEIM

6.16 BRECKENRIDGE PHARM

6.17 CIPLA LTD

6.18 AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad

6.19 Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure

6.20 CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village

6.21 CIPLA LIMITED IN 400 013 Mumbai

6.22 CRYSTAL PHARMA S.A.U. ES 47151 Boecillo

6.23 DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad

6.24 EXCELLA GMBH & CO. KG DE 90537 Feucht

6.25 Farmak A.S. CZ 779 00 Olomouc

6.26 HETERO LABS LIMITED IN 500 018 Hyderabad

6.27 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou

6.28 MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

CHAPTER SEVEN BENIGN PROSTATIC HYPERPLASIA MEDICATION BY APPLIANCE 2012-2017

7.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Appliance 2012-2017

7.2 urinary surgery

7.3 Pharmacy

7.4 Hospital

7.5 Clinic

7.6 Consuming Habit and Preference

CHAPTER EIGHT INDUSTRY CHAIN AND SUPPLY CHAIN

8.1 Benign Prostatic Hyperplasia Medication Industry Chain Structure

8.1.1 R&D

8.1.2 Raw Materials (Components)

8.1.3 Manufacturing Plants

8.1.4 Regional Trading (Import Export and Local Sales)

8.1.5 Online Sales Channel

8.1.6 Offline Channel

8.1.7 End Users

8.2 Benign Prostatic Hyperplasia Medication Manufacturing

8.2.1 Key Components

8.2.2 Assembly Manufacturing

8.3 Consumer Preference

8.4 Behavioral Habits

8.5 Marketing Environment

CHAPTER NINE GLOBAL BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)

9.2 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)

9.3 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)

9.4 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by 5 α -reductase inhibitors (2017-2022)

9.5 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by α -receptor antagonist (2017-2022)

9.6 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Plant Preparations (2017-2022)

9.7 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Others (2017-2022)

CHAPTER TEN DEVELOPMENT TREND AND RESEARCH CONCLUSION

10.1 Development Trend

10.2 Research Conclusion

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Benign Prostatic Hyperplasia Medication Sales Volume (M), Revenue (Million USD) and Price (M)(2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume (M) and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Volume (M) by Key Players (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players 2016

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players 2017

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Key Players (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players 2016

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players 2017

Table Global Key Players Key Product Model and Market Performance

Table Global Key Players Key Target Consumers and Market Performance

Table Global Benign Prostatic Hyperplasia Medication Sales (M) by Regions (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Share by Regions (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2016

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2017

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2016

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2017

Table Global Benign Prostatic Hyperplasia Medication Price (€) by Regions (2012-2017)

Table North America Benign Prostatic Hyperplasia Medication Sales (€) by Regions (2012-2017)

Table North America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)

Table North America Benign Prostatic Hyperplasia Medication Sales Volume (€) by Key Players 2012-2017

Figure North America Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Latin America Benign Prostatic Hyperplasia Medication Sales (€) by Regions (2012-2017)

Table Latin America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)

Table Latin America Benign Prostatic Hyperplasia Medication Sales Volume (€) by Key Players (2012-2017)

Figure Latin America Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Europe Benign Prostatic Hyperplasia Medication Sales (€) by Regions (2012-2017)

Table Europe Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)

Table Europe Benign Prostatic Hyperplasia Medication Sales Volume (€) by Key Players (2012-2017)

Figure Europe Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Asia & Pacific Benign Prostatic Hyperplasia Medication Sales (€) by Regions (2012-2017)

Table Asia & Pacific Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)

Table Asia & Pacific Benign Prostatic Hyperplasia Medication Sales Volume (€) by Key Players (2012-2017)

Figure Asia & Pacific Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Africa & Middle East Benign Prostatic Hyperplasia Medication Sales (€) by Regions (2012-2017)

Table Africa & Middle East Benign Prostatic Hyperplasia Medication Revenue (Million USD)

USD) by Regions (2012-2017)

Table Africa & Middle East Benign Prostatic Hyperplasia Medication Sales Volume () by Key Players (2012-2017)

Figure Africa & Middle East Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales () by 5 α -reductase inhibitors (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5 α -reductase inhibitors (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5 α -reductase inhibitors in 2016

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by 5 α -reductase inhibitors (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5 α -reductase inhibitors (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5 α -reductase inhibitors in 2016

Table Global Benign Prostatic Hyperplasia Medication Price () by 5 α -reductase inhibitors (2012-2017)

Table Top Players of Finasteride Benign Prostatic Hyperplasia Medication Products List

Figure Global Finasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Top Players of Dutasteride Benign Prostatic Hyperplasia Medication Products List

Figure Global Dutasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Top Players of Epristeride Benign Prostatic Hyperplasia Medication Products List

Figure Global Epristeride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales () by α -receptor antagonist (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by α -receptor antagonist (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by α -receptor antagonist in 2016

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by α -receptor antagonist (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α -receptor antagonist (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α -

receptor antagonist in 2016

Table Global Benign Prostatic Hyperplasia Medication Price (€) by α -receptor antagonist (2012-2017)

Table Top Players of Pheoxbenzamine Benign Prostatic Hyperplasia Medication Products List

Figure Global Pheoxbenzamine Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Top Players of Doxazosin Benign Prostatic Hyperplasia Medication Products List

Figure Global Doxazosin Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Top Players of Alfuzosin Benign Prostatic Hyperplasia Medication Products List

Figure Global Alfuzosin Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Top Players of Terazosin Benign Prostatic Hyperplasia Medication Products List

Figure Global Terazosin Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Top Players of Prarizonaosin Benign Prostatic Hyperplasia Medication Products List

Figure Global Prarizonaosin Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales (€) by Plant Preparations (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations in 2016

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Plant Preparations (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations in 2016

Table Global Benign Prostatic Hyperplasia Medication Price (€) by Plant Preparations (2012-2017)

Table Top Players of Prostat Benign Prostatic Hyperplasia Medication Products List

Figure Global Prostat Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Table Top Players of Cernilton Benign Prostatic Hyperplasia Medication Products List

Figure Global Cernilton Benign Prostatic Hyperplasia Medication Sales (€) and Growth

Rate (2012-2017)

Table Top Players of Compound blue palm fruit Benign Prostatic Hyperplasia Medication Products List

Figure Global Compound blue palm fruit Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales () by Others (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others in 2016

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Others (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others in 2016

Table Global Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)

Table Top Players of Flavoxate Benign Prostatic Hyperplasia Medication Products List

Figure Global Flavoxate Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Top Players of glu-ala-glycine Benign Prostatic Hyperplasia Medication Products List

Figure Global glu-ala-glycine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales () by (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by in 2016

Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by (2012-2017)

Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by in 2016

Table Global Benign Prostatic Hyperplasia Medication Price () by (2012-2017)

Table MSD PHARMA (SINGAPORE) PTE.LTD. Company Details and Competitors

Table MSD PHARMA (SINGAPORE) PTE.LTD. Key Benign Prostatic Hyperplasia Medication Models and Performance

Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia

Medication Business SWOT Analysis and Forecast

Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table Merck Sharp & Dohme Limited Company Details and Competitors

Table Merck Sharp & Dohme Limited Key Benign Prostatic Hyperplasia Medication Models and Performance

Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table GlaxoSmithKline (Ireland) Limited Company Details and Competitors

Table GlaxoSmithKline (Ireland) Limited Key Benign Prostatic Hyperplasia Medication Models and Performance

Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication

Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)

Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table Pfizer Pharma GmbH Company Details and Competitors

Table Pfizer Pharma GmbH Key Benign Prostatic Hyperplasia Medication Models and Performance

Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales(Million Unit) and Growth Rate (%)(2012-2017)

Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)

Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table Sanofi-Aventis France Company Details and Competitors

Table Sanofi-Aventis France Key Benign Prostatic Hyperplasia Medication Models and Performance

Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales(Million Unit) and Growth Rate (%)(2012-2017)

Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)

Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table ABBOTT LABORATORIES Company Details and Competitors

Table ABBOTT LABORATORIES Key Benign Prostatic Hyperplasia Medication Models and Performance

Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Output (),

Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication

Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales

Market Share (%) in Global (2012-2017)

Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales

Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Revenue

Market Share (%) in Global (2012-2017)

Table Astellas Pharma Inc. Company Details and Competitors

Table Astellas Pharma Inc. Key Benign Prostatic Hyperplasia Medication Models and Performance

Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table AMNEAL PHARMS Company Details and Competitors

Table AMNEAL PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance

Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table ANCHEN PHARMS Company Details and Competitors

Table ANCHEN PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance

Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table APOTEX INC Company Details and Competitors

Table APOTEX INC Key Benign Prostatic Hyperplasia Medication Models and Performance

Table APOTEX INC Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast

Table APOTEX INC Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)

Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure APOTEX INC Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)

Table ASCENT PHARMS INC Company Details and Competitors

Table AUROBINDO PHARMA Company Details and Competitors

Table BARR Company Details and Competitors

Table BIONPHARMA INC Company Details and Competitors

Table BOEHRINGER INGELHEIM Company Details and Competitors

Table BRECKENRIDGE PHARM Company Details and Competitors

Table CIPLA LTD Company Details and Competitors

Table AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad Company Details and Competitors

Table Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure Company Details and Competitors
Table CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village Company Details and Competitors

Table CIPLA LIMITED IN 400 013 Mumbai Company Details and Competitors

Table CRYSTAL PHARMA S.A.U. ES 47151 Boecillo Company Details and Competitors

Table DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad Company Details and Competitors

Table EXCELLA GMBH & CO. KG DE 90537 Feucht Company Details and Competitors

Table Farmak A.S. CZ 779 00 Olomouc Company Details and Competitors

Table HETERO LABS LIMITED IN 500 018 Hyderabad Company Details and Competitors

Table Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou Company Details and Competitors

Table MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village Company Details and Competitors

Table Global Benign Prostatic Hyperplasia Medication Sales (€) by Appliance (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Appliance (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Appliance in 2016

Figure Global urinary surgery Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Figure Global Pharmacy Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Figure Global Hospital Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Figure Global Clinic Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (2012-2017)

Figure Global Benign Prostatic Hyperplasia Medication Sales (€) and Growth Rate (%) Forecast (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Price (€) Trend Forecast (2017-2022)

Table Global Benign Prostatic Hyperplasia Medication Sales (€) Forecast by Regions (2017-2022)

Table Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by

Regions (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions in 2022

Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application in 2022

Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by 5 α -reductase inhibitors (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by 5 α -reductase inhibitors (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by 5 α -reductase inhibitors in 2022

Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by α -receptor antagonist (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by α -receptor antagonist (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by α -receptor antagonist in 2022

Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Plant Preparations (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Plant Preparations (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Plant Preparations in 2022

Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Others (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Others (2017-2022)

Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Others in 2022

I would like to order

Product name: Global Benign Prostatic Hyperplasia Medication Market Research Report 2017-2022 by Players, Regions, Product Types & Applications

Product link: <https://marketpublishers.com/r/G6B95A3FCBFEN.html>

Price: US\$ 2,380.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6B95A3FCBFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

